STANFORD, Calif. - "Serendipity" rather than science plays a prominent role in the current diagnosis of prostate cancer, according to Stanford University Medical Center researchers. A new study finds ...

PALO ALTO, Calif. -- Doctors at Stanford Hospital are using a powerful new technology to help men battle of common form of cancer. It's allowing them to make decisions with more confidence than ever ...

After more than 30 years at Fred Hutchinson Cancer Research Center, primarily studying prostate cancer genetics, risk factors and treatment outcomes, faculty member Dr. Janet Stanford has retired. She ...

From Seattle to Sweden: first population-based study to demonstrate that inherited genetic variants play a role in prostate cancer progression and mortality SEATTLE — Aug. 16, 2011 — An international ...

The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine ...

Middle-aged men who are long-term, heavy smokers face twice the risk of developing more aggressive forms of prostate cancer than men who have never smoked, according to new findings from Fred ...

Janet Stanford has been studying prostate cancer for years; she knows the statistics and can recite them from memory: Prostate cancer is the second most common cause of death from cancer in men in the ...

A new study associates five genetic markers with fatal cases of prostate cancer. During the 6.5-year study of prostate cancer patients, those who had four or all five of these genetic markers were 50 ...

For aging men, prostate enlargement is almost as common as graying hair, and yet scientists know very little about why the prostate increases in size or how the process occurs on a molecular level. In ...

As far as Bill Robnett knows, he does not have prostate cancer, and he would like it to stay that way. At 65, the Monterey resident is aware that his age puts him at risk for prostate cancer, the ...

A San Francisco, California-based medical device startup, Zenflow, has announced a $31.4 million Series A financing round to further its minimally-invasive approach to treating benign prostatic ...